Fresenius Medical Care AG (FMS)
20.21
-0.55
(-2.65%)
USD |
NYSE |
Apr 25, 16:00
20.22
+0.01
(+0.05%)
After-Hours: 20:00
Fresenius Medical Care SG&A Expense (Quarterly): 910.16M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 910.16M |
September 30, 2023 | 864.27M |
June 30, 2023 | 845.34M |
March 31, 2023 | 840.06M |
December 31, 2022 | 823.41M |
September 30, 2022 | 823.21M |
June 30, 2022 | 807.34M |
March 31, 2022 | 886.44M |
December 31, 2021 | 571.75M |
September 30, 2021 | 862.16M |
June 30, 2021 | 1.001B |
March 31, 2021 | 857.39M |
December 31, 2020 | 1.080B |
September 30, 2020 | 826.35M |
June 30, 2020 | 783.40M |
March 31, 2020 | 893.78M |
December 31, 2019 | 869.47M |
September 30, 2019 | 813.27M |
June 30, 2019 | 893.28M |
March 31, 2019 | 818.07M |
December 31, 2018 | 854.10M |
September 30, 2018 | 863.56M |
June 30, 2018 | 853.94M |
March 31, 2018 | 833.87M |
December 31, 2017 | 1.188B |
Date | Value |
---|---|
September 30, 2017 | 942.65M |
June 30, 2017 | 994.69M |
March 31, 2017 | 983.39M |
December 31, 2016 | 865.18M |
September 30, 2016 | 882.70M |
June 30, 2016 | 858.38M |
March 31, 2016 | 860.59M |
December 31, 2015 | 1.165B |
September 30, 2015 | 733.18M |
June 30, 2015 | 711.96M |
March 31, 2015 | 682.37M |
December 31, 2014 | 824.32M |
September 30, 2014 | 701.19M |
June 30, 2014 | 633.76M |
March 31, 2014 | 617.34M |
December 31, 2013 | 561.49M |
September 30, 2013 | 574.20M |
June 30, 2013 | 597.71M |
March 31, 2013 | 609.99M |
December 31, 2012 | 550.92M |
September 30, 2012 | 508.42M |
June 30, 2012 | 547.30M |
March 31, 2012 | 543.35M |
December 31, 2011 | 602.17M |
September 30, 2011 | 525.38M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
571.75M
Minimum
Dec 2021
1.080B
Maximum
Dec 2020
855.35M
Average
857.39M
Median
Mar 2021
SG&A Expense (Quarterly) Benchmarks
Biodexa Pharmaceuticals Plc | -- |
NuCana PLC | 1.597M |
Biophytis SA | -- |
TC BioPharm (Holdings) PLC | -- |
DaVita Inc | 401.47M |